Dr. Aggarwal on Androgen Deprivation Therapy for Prostate Cancer

Rahul Aggarwal, MD
Published: Friday, Sep 29, 2017



Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.

According to Aggarwal, we are moving away from a one-size-fits-all approach for androgen deprivation therapy to one that is adaptive for a patient’s specific disease state. Physicians are focused on the recent data in regards to abiraterone (Zytiga) and AR-targeted therapies.
 


Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.

According to Aggarwal, we are moving away from a one-size-fits-all approach for androgen deprivation therapy to one that is adaptive for a patient’s specific disease state. Physicians are focused on the recent data in regards to abiraterone (Zytiga) and AR-targeted therapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x